Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study-Reference-Cited by-同舟云学术

Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study

Published:2023-01 Issue:1 Volume:28 Page:100769
ISSN:1665-2681
Container-title:Annals of Hepatology
language:en
Short-container-title:Annals of Hepatology

Author:

Barcelos Samantha Thifani Alrutz,Silva-Sperb Amanda Souza,Moraes Helena Abadie,Longo Larisse,de Moura Bruna Concheski,Michalczuk Matheus Truccolo,Uribe-Cruz Carolina,Cerski Carlos Thadeu Schmidt,da Silveira Themis Reverbel,Dall'Alba Valesca^ORCID,Álvares-da-Silva Mário Reis

Funder

Hospital de Clínicas de Porto Alegre

Publisher

Elsevier BV

Subject

Hepatology,General Medicine

Reference67 articles.

1. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement;Eslam;J Hepatol,2020

2. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis;Younossi;Hepatology,2019

3. Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

4. Non-alcoholic fatty liver disease and cardiovascular risk;Patil;World J Gastrointest Pathophysiol,2017

5. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease;Eslam;Gastroenterology,2020

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Probiotics in Managing Metabolic-Associated Fatty Liver Disease: An Updated Review;Current Research in Nutrition and Food Science Journal;2024-08-30

2. Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials;BMC Gastroenterology;2024-08-22

3. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis;Clinical Nutrition;2024-06

4. Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases;Journal of Medicinal Food;2024-06-01

5. Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial;Frontiers in Nutrition;2024-03-27